We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Human Milk for Congenital Gastrointestinal Disorders (HM for CGD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02567292
Recruitment Status : Completed
First Posted : October 2, 2015
Last Update Posted : August 31, 2022
Sponsor:
Collaborators:
Chatham Valley Foundation
Prolacta Bioscience
Information provided by (Responsible Party):
Heidi Karpen, Emory University

Tracking Information
First Submitted Date  ICMJE October 1, 2015
First Posted Date  ICMJE October 2, 2015
Last Update Posted Date August 31, 2022
Actual Study Start Date  ICMJE July 26, 2018
Actual Primary Completion Date January 18, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 26, 2018)
Time to full enteral feeding [ Time Frame: From birth to day of life full enteral feedings for 7 days is achieved (up to 30 days) ]
The number of days to achieve full enteral feeding after the initial human milk feeding
Original Primary Outcome Measures  ICMJE
 (submitted: October 1, 2015)
Length of hospital stay [ Time Frame: Post initial feeding (Up to ten days) ]
The length of hospital stay described as the number of days spent in the hospital after the initial breast milk feeding.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 26, 2018)
  • Number of days of parenteral nutrition [ Time Frame: Through study completion, up to 1 year ]
    The total number of days parenteral nutrition is required.
  • Length of hospital stay [ Time Frame: Through study completion, up to 6 months ]
    The length of hospital stay described as the number of days spent in the hospital
  • Difference in conjugated bilirubin levels [ Time Frame: From birth to day of life full enteral feedings for 7 days is achieved (up to 30 days) ]
    The difference in average bilirubin level will be compared between the non-human milk diet (retrospective control group) and the breast milk diet group.
  • Feeding intolerance [ Time Frame: From birth to day of life full enteral feedings for 7 days is achieved (up to 30 days) ]
    Number of days when one or more feedings were held for clinical concerns
  • Feeding interruptions [ Time Frame: From birth to day of life full enteral feedings for 7 days is achieved (up to 30 days) ]
    NPO for at least 24 hours. NPO due to elective surgeries or procedures will not be defined as feeding interruptions
  • Episodes of Necrotizing Enterocolitis [ Time Frame: From birth to day of life full enteral feedings for 7 days is achieved (up to 30 days) ]
    Number of episodes of Stage IIb NEC or greater
  • Number of sepsis episodes [ Time Frame: From birth to day of life full enteral feedings for 7 days is achieved (up to 30 days) ]
    The number of sepsis episodes will be compared between the non-breast milk diet (retrospective control group) and the breast milk diet group.
  • Death rate [ Time Frame: Through study completion, up to 1 year ]
    The number of deaths between participants who receive breast milk only diets as compared to the non-breast milk diet (retrospective control group while in the neonatal intensive care unit (NICU).
Original Secondary Outcome Measures  ICMJE
 (submitted: October 1, 2015)
  • Time to full enteral feeding [ Time Frame: Post initial feeding (Up to ten days) ]
    The number of days to achieve full enteral feeding after the initial breast milk feeding.
  • Number of days of parenteral nutrition [ Time Frame: Post initial feeding (Up to ten days) ]
    The total number of days parenteral nutrition is required.
  • Difference in bilirubin levels [ Time Frame: Post initial feeding (Up to ten days) ]
    The difference in average bilirubin level will be compared between the non-breast milk diet (retrospective control group) and the breast milk diet group.
  • Number of sepsis episodes [ Time Frame: Post initial feeding (Up to ten days) ]
    The number of sepsis episodes will be compared between the non-breast milk diet (retrospective control group) and the breast milk diet group.
  • Death rate [ Time Frame: Post initial feeding (Up to ten days) ]
    The number of deaths between participants who receive breast milk only diets as compared to the non-breast milk diet (retrospective control group while in the neonatal intensive care unit (NICU).
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Human Milk for Congenital Gastrointestinal Disorders
Official Title  ICMJE Effects of an Exclusive Human Milk Diet on Enteral Feeding Outcomes of Neonates With Congenital Gastrointestinal Disorders
Brief Summary This study aims to identify whether an exclusive human milk diet (EHMD) would improve outcomes in neonates with congenital gastrointestinal disorders (CGD) and by facilitating an earlier transition off of parenteral nutrition (PN).
Detailed Description

Infants born with congenital gastrointestinal disorders (CGD) can be very challenging to treat. The CGD require surgery shortly after birth to correct the problems and recovery can take a long time.

During the period of time the infant's intestines are sick or don't work properly, they rely on parenteral nutrition (IV fluids containing carbohydrates, proteins and fats) to meet their nutritional needs. Being on PN for a long time requires special intravenous lines, and increases the risk of blood stream infections and can make the liver sick.

Feeding babies who have these CGD is often very difficult, as the intestine needs to adapt. It needs to make appropriately formed stool to eliminate wastes, but not lose too much water or too many electrolytes. There is often a lot of starting and stopping of feeds. Human milk (HM) is considered the ideal source of nutrition for all infants.

This study aims to identify whether an exclusive human milk diet (EHMD) would improve outcomes in neonates with congenital gastrointestinal disorders (CGD) and by facilitating an earlier transition off of parenteral nutrition (PN).

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Condition  ICMJE Congenital Gastrointestinal Disorders
Intervention  ICMJE Other: Human Milk
Participants will receive an exclusive human milk diet comprised of mother's own milk (MOM, pasteurized donor human milk (DM) fortified with a donor-milk based fortifier (DMBF): Prolact+ for infants <37 weeks PMA and/or or weight <2,200g or PBCLN-002 for infants >37 weeks PMA and/or weight >2,200g)
Study Arms  ICMJE
  • No Intervention: Retrospective Control Group
    Approximately 150 patients with congenital gastrointestinal disorders who were treated in the neonatal intensive care unit (NICU) at Children's Healthcare of Atlanta-Egleston and other participating institutions from 2012 to 2015, who had non-human milk (HM) diets will be identified as retrospective controls using the electronic medical records system.
  • Experimental: Exclusive Human Milk Diet Group
    A minimum of 150 patients with CGD admitted to participating NICUs who meet inclusion criteria and provide informed consent will be enrolled in the prospective arm of the study. These patients will be fed an EHMD comprised of mother's own milk (MOM) or pasteurized donor human milk (DM). Fortification will be provided with human milk derived human milk fortifier, either a human milk-based fortifier (Prolact+ H2MF®) for infants born at less than 37 weeks GA or <2,200g birth weight or the term-equivalent version (PBCLN-002) formulated for infants >37 weeks and/or >2,200g at birth. Infants will receive this EHMD until they have achieved full enteral feedings for 7 days with bowel in continuity
    Intervention: Other: Human Milk
Publications * Shinnick JK, Wang E, Hulbert C, McCracken C, Sarson GY, Piazza A, Karpen H, Durham MM. Effects of a Breast Milk Diet on Enteral Feeding Outcomes of Neonates with Gastrointestinal Disorders. Breastfeed Med. 2016 Aug;11(6):286-292. doi: 10.1089/bfm.2016.0002. Epub 2016 Jun 22.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 26, 2022)
151
Original Estimated Enrollment  ICMJE
 (submitted: October 1, 2015)
100
Actual Study Completion Date  ICMJE January 18, 2022
Actual Primary Completion Date January 18, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Admission to participating NICU at less than 7 days of age
  2. Birthweight >1250g and/or gestational age at birth >32 weeks
  3. Less than 7 days of enteral feedings
  4. Diagnosis of eligible primary "Congenital Gastointestinal Disorders" defined as: gastroschisis, omphalocele and intestinal atresias
  5. Consent to the use of donor human milk products
  6. Consent to participate in this study

Exclusion Criteria:

  1. Admission to participating NICU at >7 days of age
  2. Birthweight <1250g and/or gestational age <32 weeks
  3. Diagnosis of non-eligible gastrointestinal disorders: congenital diaphragmatic hernia, midgut volvulus, Hirschsprung's disease, esophageal atresia, imperforate anus
  4. Evidence of significant liver dysfunction at time of enrollment (direct bilirubin >4 and transaminases elevated more than 2 SD above upper limit of normal for age)
  5. Liver malformations such as biliary atresia and choledochal cyst
  6. Refusal of consent
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 1 Minute to 1 Year   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02567292
Other Study ID Numbers  ICMJE IRB00080481
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Heidi Karpen, Emory University
Original Responsible Party Megan Durham, Emory University, Associate Professor
Current Study Sponsor  ICMJE Emory University
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE
  • Chatham Valley Foundation
  • Prolacta Bioscience
Investigators  ICMJE
Principal Investigator: Heidi Karpen, MD Emory University
PRS Account Emory University
Verification Date August 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP